New York – August 25, 2017 – Cooley advised the underwriters on Zealand Pharma A/S’s $89 million initial public offering of 5,031,250 American Depositary Shares in the United States, which includes the full exercise of the underwriters’ option to purchase additional shares. Capital markets partners Josh Kaufman, Div Gupta and Charlie Kim led the team advising the underwriters.
Morgan Stanley and Goldman Sachs & Co. LLC acted as joint book-running managers and Guggenheim Securities and Needham & Company acted as co-managers. This IPO marks the first dual listing of a Danish company on NASDAQ and NASDAQ Copenhagen.
Zealand, which now trades on The NASDAQ Global Select Market and NASDAQ Copenhagen under the ticker symbol “ZEAL,” is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.